Milestone
Every feather in our crown is evidence of Zenovel’s Commitment, Proficiency, and Relentess Search towards Excellence
Every feather in our crown is evidence of Zenovel’s Commitment, Proficiency, and Relentess Search towards Excellence
In 2023, Zenovel proudly completed 332 Audit Days, strengthening trust with over 50 clients and delivering 103 high-quality Audit Reports. 🏆
Our global footprint extends across major markets, including India, China, and the USA, navigating regulatory scrutiny from the USFDA and EMA. 🌐
We maintained the highest GMP standards across all operations, from APIs to Finished Formulations, ensuring excellence in Plant Set-ups, QMS Upgrades, and more.
In 2023, Zenovel embarked on a transformative journey, achieving remarkable milestones in clinical research organization. Conducting 210 global studies, we continued to push boundaries with cutting-edge methodologies.
Our dedication to Data Integrity, Electronic Compliance and Diverse Pre-Clinical Studies sets us apart as leaders in the field.
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
Welcome to the Zenovel Blog! We are a leading provider of drug regulatory consulting and education, focusing on advancing pharmaceutical innovation while ensuring safety and compliance. This blog delves into the essentials of Drug Regulatory Affairs (DRA), covering its scope, career opportunities, and intricate processes involved in bringing new drugs
The international pharmaceutical landscape is inherently connected to the global economy and global trade, which is consisted with the quality and safety assurance , well-controlled quality and safety. Compliance with international pharmaceutical standards has changed from an optional step to a requirement. The Pharmaceutical Inspection Co-operation Scheme (PIC/S Certification) is
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Copyright © 2024 Zenovel. All rights reserved.